PA
KRYS icon

Profund Advisors’s Krystal Biotech KRYS Stock Holding History

Profund Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
5,770
-3,020
-34% -$902K 0.06% 181
2026
Q1 		$2.27M Sell
8,790
-1,097
-11% -$292K 0.08% 174
2025
Q4 		$2.44M Buy
9,887
+1,557
+19% +$328K 0.07% 173
2025
Q3 		$1.47M Buy
8,330
+164
+2% +$24.5K 0.05% 248
2025
Q2 		$1.12M Buy
8,166
+2,203
+37% +$324K 0.04% 277
2025
Q1 		$1.08M Sell
5,963
-358
-6% -$60.2K 0.05% 280
2024
Q4 		$990K Sell
6,321
-3,664
-37% -$650K 0.04% 301
2024
Q3 		$1.82M Buy
9,985
+1,292
+15% +$249K 0.07% 207
2024
Q2 		$1.6M Buy
8,693
+140
+2% +$23.5K 0.06% 215
2024
Q1 		$1.52M Sell
8,553
-5,229
-38% -$726K 0.06% 224
2023
Q4 		$1.71M Buy
13,782
+1,542
+13% +$171K 0.07% 203
2023
Q3 		$1.42M Buy
12,240
+2,375
+24% +$290K 0.08% 202
2023
Q2 		$1.16M Sell
9,865
-1,716
-15% -$175K 0.06% 283
2023
Q1 		$927K Buy
+11,581
New +$910K 0.06% 320

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Profund Advisors's KRYS Position: Q2 2026 in Review

Profund Advisors reduced its Krystal Biotech (KRYS) stake by 34% in Q2 2026, selling an estimated $902K and leaving 5,770 shares worth $2.14M. The position accounts for 0.06% of the portfolio, ranked #181.

Profund Advisors first reported a position in KRYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.44M in Q4 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Profund Advisors held 5,770 shares of Krystal Biotech worth $2.14M as of Q2 2026.
  • Profund Advisors sold 3,020 Krystal Biotech shares in Q2 2026, an estimated $902K.
  • Krystal Biotech made up 0.06% of Profund Advisors's portfolio in Q2 2026, its #181 holding.
  • Profund Advisors first reported a position in Krystal Biotech in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Krystal Biotech position peaked at $2.44M in Q4 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.